Guhan Pharmaceutical Group Co Ltd

Guhan Pharmaceutical Group Co Ltd has a market capitalization of CNY 2.5 billion and a price-to-book ratio of 4.57, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is characterized as medium, with a current ratio of 1.88, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at CNY -70.99 million, and its operating cash flow is CNY 28.96 million, indicating that it is not generating enough cash from operations to fund its capital expenditures. In terms of profitability, the company is currently unprofitable, with a net loss of CNY -50.52 million and an operating loss of CNY -51.20 million. Its return on equity is -9.22%, and its return on assets is -5.68%, both of which are significantly below the industry median for pharmaceutical companies. The company's gross profit margin is 44.17%, which is in line with the industry average, but its operating margin is negative, indicating that it is not able to convert its gross profit into operating profit. The company's revenue is concentrated in a single geographic market, with all of its revenue coming from China. It does not disclose any segment data, so it is unclear whether its product portfolio is diversified or if it is heavily reliant on a few key products. The company's debt-to-equity ratio is 0.18, indicating a relatively low level of leverage. Looking ahead, the company is expected to face continued challenges in the near term, with no clear signs of improvement in its financial performance. The company's operating income and net income are both negative, and there is no indication that this trend will reverse in the next fiscal year. The company's capital expenditures are also a concern, as it is spending CNY -48.81 million on capital projects, which is not being offset by positive free cash flow. The company's risk profile is moderate, with a low risk of dilution and a medium liquidity risk. However, the company's negative net cash position after subtracting total debt is a red flag, as it suggests that the company may need to raise additional capital in the near future. The company's debt-to-equity ratio is low, but its free cash flow is negative, which could lead to increased leverage if the company is forced to take on more debt to fund its operations. In the recent past, the company has not disclosed any major events or filings that would suggest a significant change in its business strategy or financial position. The company's financial performance has been declining, and there is no indication that this trend will reverse in the near future. The company's operating cash flow is positive, but it is not sufficient to cover its capital expenditures, which is a concern for investors.